First patient dosed in the MIV-818 combination study

STOCKHOLM, Dec. 14, 2021 /PRNewswire/ — Medivir AB (Nasdaq Stockholm: MVIR) today announced that the first patient with hepatocellular carcinoma (HCC) has been dosed with MIV-818 in a phase 1b/2a combination study with the company’s candidate drug MIV-818. In the study, MIV-818 will be…

No Comments

No comments yet.

Sorry, the comment form is closed at this time.